Extraintestinal manifestations of inflammatory bowel disease

SR Vavricka, A Schoepfer, M Scharl… - Inflammatory bowel …, 2015 - academic.oup.com
Extraintestinal manifestations (EIM) in inflammatory bowel disease (IBD) are frequent and
may occur before or after IBD diagnosis. EIM may impact the quality of life for patients with …

Risk factors, clinical features and treatment of Behçet's disease uveitis

Z Zhong, G Su, P Yang - Progress in Retinal and Eye Research, 2023 - Elsevier
Behçet's disease is a systemic vasculitis frequently associated with intraocular inflammation.
Recent findings identified independent clinical clusters in Behçet's disease, each involving …

2018 update of the EULAR recommendations for the management of Behçet's syndrome

G Hatemi, R Christensen, D Bang, B Bodaghi… - Annals of the …, 2018 - ard.bmj.com
Several new treatment modalities with different mechanisms of action have been studied in
patients with Behçet's syndrome (BS). The aim of the current effort was to update the …

Efficacy of anti-TNF alpha in severe and/or refractory Behçet's disease: multicenter study of 124 patients

H Vallet, S Riviere, A Sanna, A Deroux, G Moulis… - Journal of …, 2015 - Elsevier
Objective To report the efficacy and safety of anti-TNF agents in patients with severe and/or
refractory manifestations of Behçet's disease (BD). Methods We performed a multicenter …

Anti-IL6-receptor tocilizumab in refractory and noninfectious uveitic cystoid macular edema: multicenter study of 25 patients

N Vegas-Revenga, V Calvo-Río, M Mesquida… - American Journal of …, 2019 - Elsevier
Purpose Cystoid macular edema (CME) is a leading cause of blindness. This study
assessed the efficacy and safety of tocilizumab (TCZ) in refractory CME. Design …

Tocilizumab in giant cell arteritis. Observational, open-label multicenter study of 134 patients in clinical practice

M Calderón-Goercke, J Loricera, V Aldasoro… - Seminars in arthritis and …, 2019 - Elsevier
Objective: Tocilizumab (TCZ) has shown efficacy in clinical trials on giant cell arteritis (GCA).
Real-world data are scarce. Our objective was to assess efficacy and safety of TCZ in …

Anti–interleukin‐6 receptor tocilizumab for severe juvenile idiopathic arthritis–associated uveitis refractory to anti–tumor necrosis factor therapy: a multicenter study of …

V Calvo‐Río, M Santos‐Gómez, I Calvo… - Arthritis & …, 2017 - Wiley Online Library
Objective To assess the efficacy of tocilizumab (TCZ) for the treatment of juvenile idiopathic
arthritis (JIA)–associated uveitis. Methods We conducted a multicenter study of patients with …

Management of major organ involvement of Behçet's syndrome: a systematic review for update of the EULAR recommendations

Y Ozguler, P Leccese, R Christensen… - …, 2018 - academic.oup.com
Objective To assess the efficacy and safety of treatment modalities for major organ
involvement of Behçet's syndrome (BS), in order to inform the update of the EULAR …

Anti-interleukin 6 receptor tocilizumab in refractory uveitis associated with Behçet's disease: multicentre retrospective study

B Atienza-Mateo, V Calvo-Río, E Beltran… - …, 2018 - academic.oup.com
Objective To assess the efficacy of tocilizumab (TCZ) in refractory uveitis of Behçet's disease
(BD). Methods Multicentre study of patients with BD-associated uveitis. Patients were …

Infliximab versus adalimumab in the treatment of refractory inflammatory uveitis: a multicenter study from the French Uveitis Network

H Vallet, P Seve, L Biard… - Arthritis & …, 2016 - Wiley Online Library
Objective To analyze the factors associated with response to anti–tumor necrosis factor (anti‐
TNF) treatment and compare the efficacy and safety of infliximab (IFX) and adalimumab …